STAAR Surgical (NASDAQ:STAA) was the recipient of some unusual options trading on Wednesday. Traders acquired 2,200 call options on the company. This represents an increase of 1,847% compared to the average volume of 113 call options.

In related news, CEO Caren L. Mason sold 7,500 shares of STAAR Surgical stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $36.25, for a total value of $271,875.00. Following the sale, the chief executive officer now directly owns 44,013 shares in the company, valued at $1,595,471.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Samuel J. Gesten sold 1,500 shares of STAAR Surgical stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $36.20, for a total value of $54,300.00. Following the completion of the sale, the insider now owns 36,816 shares in the company, valued at $1,332,739.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,730 shares of company stock worth $655,538. Company insiders own 3.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in STAAR Surgical by 1.4% during the fourth quarter. BlackRock Inc. now owns 3,111,085 shares of the medical instruments supplier’s stock worth $99,276,000 after purchasing an additional 42,395 shares during the last quarter. Vanguard Group Inc raised its holdings in STAAR Surgical by 60.9% during the third quarter. Vanguard Group Inc now owns 2,754,944 shares of the medical instruments supplier’s stock worth $132,238,000 after purchasing an additional 1,042,724 shares during the last quarter. Vanguard Group Inc. raised its holdings in STAAR Surgical by 60.9% during the third quarter. Vanguard Group Inc. now owns 2,754,944 shares of the medical instruments supplier’s stock worth $132,238,000 after purchasing an additional 1,042,724 shares during the last quarter. Baillie Gifford & Co. raised its holdings in STAAR Surgical by 10.0% during the fourth quarter. Baillie Gifford & Co. now owns 1,705,521 shares of the medical instruments supplier’s stock worth $54,424,000 after purchasing an additional 155,342 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in STAAR Surgical by 46.4% during the third quarter. Renaissance Technologies LLC now owns 906,000 shares of the medical instruments supplier’s stock worth $43,488,000 after purchasing an additional 287,000 shares during the last quarter. 89.92% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on STAA. BidaskClub upgraded STAAR Surgical from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. ValuEngine downgraded STAAR Surgical from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 21st. Zacks Investment Research downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, March 2nd. Finally, TheStreet downgraded STAAR Surgical from a “b-” rating to a “c” rating in a research note on Friday, December 14th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. STAAR Surgical presently has an average rating of “Buy” and a consensus target price of $45.25.

Shares of STAA stock opened at $37.01 on Thursday. The firm has a market cap of $1.56 billion, a P/E ratio of 130.44 and a beta of 2.10. STAAR Surgical has a 1 year low of $13.60 and a 1 year high of $54.00.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Thursday, February 21st. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.01. The firm had revenue of $31.19 million during the quarter, compared to analysts’ expectations of $31.20 million. STAAR Surgical had a return on equity of 13.86% and a net margin of 4.01%. Analysts predict that STAAR Surgical will post 0.3 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/staar-surgical-sees-unusually-large-options-volume-staa/2954313.html.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Read More: How is a buy-side analyst different from a sell-side analyst?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.